The North America hemostatic sealants in arterial surgery market size was estimated at USD 100.0 million in 2025 and is projected to grow from USD 102.3 million in 2026 to USD 119.6 million by 2033, at a CAGR of 2.3% from 2026 to 2033. The growth is driven by the increasing demand for effective intraoperative bleeding management during complex vascular procedures.
Arterial surgeries such as aortic aneurysm repair, peripheral bypass grafting, carotid endarterectomy, and vascular reconstruction frequently involve significant bleeding risks due to high-pressure blood flow and the widespread use of anticoagulant therapies among cardiovascular patients. As a result, hospitals and vascular surgeons are increasingly adopting topical hemostatic sealants as adjunctive technologies to enhance surgical precision, reduce blood loss, and improve procedural outcomes.
The market is benefiting from the growing clinical emphasis on reducing operative complications, shortening procedure duration, and minimizing the need for blood transfusions or surgical reinterventions. Hemostatic sealants are increasingly used to reinforce vascular anastomoses, seal needle-hole bleeding, and support suture-line integrity during arterial repair procedures. Their ability to achieve rapid hemostasis has made them particularly valuable in high-risk surgeries involving fragile vascular tissue, calcified arteries, or elderly patients with multiple comorbidities.
A major factor supporting market expansion is the strengthening body of clinical evidence validating the effectiveness of sealants in vascular surgery. In May 2024, an updated Cochrane systematic review titled “The role of sealants for achieving anastomotic hemostasis in vascular surgery” evaluated 24 randomized controlled trials involving more than 2,300 vascular surgery patients. The analysis demonstrated that sealant use significantly reduced time to hemostasis compared with conventional approaches such as manual compression, gelatin sponges, and oxidized cellulose-based agents. The review also highlighted lower rates of hemostatic intervention failure, reinforcing surgeon confidence in sealant-assisted vascular closure techniques.
Commercial adoption across North America continues to expand, driven by the widespread use of advanced fibrin-based and synthetic sealant products, including TISSEEL, EVICEL, BioGlue, COSEAL, and SURGIFLO. These products are increasingly used in hospitals and vascular surgery centers due to their rapid polymerization, strong tissue adhesion, ease of application, and compatibility with both open and minimally invasive surgical approaches.
The rising prevalence of cardiovascular diseases across the U.S. and Canada is further contributing to procedural growth in arterial surgery. Increasing incidences of peripheral artery disease, abdominal aortic aneurysms, diabetes-associated vascular complications, and traumatic vascular injuries are leading to higher volumes of vascular interventions. In parallel, the rapidly aging population across North America is increasing the number of elderly patients requiring arterial reconstruction and bypass procedures, thereby expanding the demand for advanced intraoperative bleeding control solutions.
Minimally invasive aortic valve replacement (MIAVR) procedures are also gaining strong adoption across cardiac centers. A study published by the National Library of Medicine reported that MIAVR significantly reduces postoperative pain, blood transfusion requirements, respiratory complications, wound infections, ICU stays, and hospitalization duration compared to conventional sternotomy procedures. The study further highlighted improved cosmetic outcomes, earlier mobilization, and lower overall surgical trauma.
This product will be delivered within 1-3 business days.
Arterial surgeries such as aortic aneurysm repair, peripheral bypass grafting, carotid endarterectomy, and vascular reconstruction frequently involve significant bleeding risks due to high-pressure blood flow and the widespread use of anticoagulant therapies among cardiovascular patients. As a result, hospitals and vascular surgeons are increasingly adopting topical hemostatic sealants as adjunctive technologies to enhance surgical precision, reduce blood loss, and improve procedural outcomes.
The market is benefiting from the growing clinical emphasis on reducing operative complications, shortening procedure duration, and minimizing the need for blood transfusions or surgical reinterventions. Hemostatic sealants are increasingly used to reinforce vascular anastomoses, seal needle-hole bleeding, and support suture-line integrity during arterial repair procedures. Their ability to achieve rapid hemostasis has made them particularly valuable in high-risk surgeries involving fragile vascular tissue, calcified arteries, or elderly patients with multiple comorbidities.
A major factor supporting market expansion is the strengthening body of clinical evidence validating the effectiveness of sealants in vascular surgery. In May 2024, an updated Cochrane systematic review titled “The role of sealants for achieving anastomotic hemostasis in vascular surgery” evaluated 24 randomized controlled trials involving more than 2,300 vascular surgery patients. The analysis demonstrated that sealant use significantly reduced time to hemostasis compared with conventional approaches such as manual compression, gelatin sponges, and oxidized cellulose-based agents. The review also highlighted lower rates of hemostatic intervention failure, reinforcing surgeon confidence in sealant-assisted vascular closure techniques.
Commercial adoption across North America continues to expand, driven by the widespread use of advanced fibrin-based and synthetic sealant products, including TISSEEL, EVICEL, BioGlue, COSEAL, and SURGIFLO. These products are increasingly used in hospitals and vascular surgery centers due to their rapid polymerization, strong tissue adhesion, ease of application, and compatibility with both open and minimally invasive surgical approaches.
The rising prevalence of cardiovascular diseases across the U.S. and Canada is further contributing to procedural growth in arterial surgery. Increasing incidences of peripheral artery disease, abdominal aortic aneurysms, diabetes-associated vascular complications, and traumatic vascular injuries are leading to higher volumes of vascular interventions. In parallel, the rapidly aging population across North America is increasing the number of elderly patients requiring arterial reconstruction and bypass procedures, thereby expanding the demand for advanced intraoperative bleeding control solutions.
Minimally invasive aortic valve replacement (MIAVR) procedures are also gaining strong adoption across cardiac centers. A study published by the National Library of Medicine reported that MIAVR significantly reduces postoperative pain, blood transfusion requirements, respiratory complications, wound infections, ICU stays, and hospitalization duration compared to conventional sternotomy procedures. The study further highlighted improved cosmetic outcomes, earlier mobilization, and lower overall surgical trauma.
North America Hemostatic Sealants In Arterial Surgery Market Report Segmentation
This report forecasts revenue growth at regional and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. Forthis study, the analyst has segmented the North America hemostatic sealants in arterial surgery market report based on product, application, disease indication, end use, and country:Product Outlook (Revenue, USD Unit, 2021-2033)
- Fibrin-Based Sealants
- Synthetic/Polymer-Based Sealants
- Combination Hemostats & Sealants
Application Outlook (Revenue, USD Unit, 2021-2033)
- Arterial Surgery With Graft Replacement
- Arterial Repair/Reconstruction Without Graft
Disease Indication Outlook (Revenue, USD Unit, 2021-2033)
- Aortic Aneurysms
- Peripheral Artery Disease
- Carotid Artery Disease
- Others
End Use Outlook (Revenue, USD Unit, 2021-2033)
- Public Hospitals
- Private Hospitals
Country Outlook (Revenue, USD Unit, 2021-2033)
- U.S.
- Canada
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. North America Hemostatic Sealants In Arterial Surgery Market Variables, Trends & Scope
Chapter 4. North America Hemostatic Sealants In Arterial Surgery Market: Product Estimates & Trend Analysis
Chapter 5. North America Hemostatic Sealants In Arterial Surgery Market: Application Estimates & Trend Analysis
Chapter 6. North America Hemostatic Sealants In Arterial Surgery Market: Disease Indication Estimates & Trend Analysis
Chapter 7. North America Hemostatic Sealants In Arterial Surgery Market: End Use Estimates & Trend Analysis
Chapter 8. North America Hemostatic Sealants In Arterial Surgery Market: Regional Estimates & Trend Analysis
Chapter 9. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Ethicon
- Baxter International
- Corza Medical
- Integra LifeSciences Corporation
- Artivion
- Becton, Dickinson and Company (BD)
- Teleflex
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 140 |
| Published | May 2026 |
| Forecast Period | 2025 - 2033 |
| Estimated Market Value ( USD | $ 100 Million |
| Forecasted Market Value ( USD | $ 119.6 Million |
| Compound Annual Growth Rate | 2.3% |
| Regions Covered | North America |
| No. of Companies Mentioned | 7 |
